A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma

30 Mar 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Relapsed/Refractory Multiple Myeloma · Phase EARLY_PHASE1 · Enrollment 30 · Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Cardiology on 30 Mar 2026. The item focuses on A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma. Open the detail page to review the full original feed content.